Abstract:BackgroundBetween 25%-50% of patients hospitalized with (COVID-19) suffer cardiovascular events. Limited information is available to identify those at greatest risk for cardiac complications.ObjectivesObjectives were to analyze risk factors associated with cardiovascular events (CE); analyze whether risk factors and outcomes were influenced by race; and analyze survival differences among various groups.MethodsThis retrospective cohort study of 700 inpatients with COVID-19 was conducted at nine hospitals within a large urban midwestern city. Data was collected from March 9, 2020, to June 20, 2020. Inclusion criteria included all COVID-19 inpatients and excluded non-inpatients. Predictor variables included demographics, comorbidities, and current clinical data. The outcomes were heart failure (HF), deep-vein thrombosis, myocardial infarction, pulmonary edema, stroke, cardiomyopathy, myocarditis, reduced ejection fraction, cardiac arrhythmias, cardiogenic shock, and cardiac arrest. Pearson's correlation coefficients were used to evaluate the correlation between different variables. Multiple logistics regression analyses were conducted to examine which variables predict cardiovascular events for the entire cohort, African American patients, and white patients, respectively. Mann-Whitney U, Chi-square, or Fisher's exact tests were used to examine differences in groups with and without CE and Kaplan-Meier was conducted for survival comparisons between groups.ResultsOf 700 COVID-19 positive inpatients, 126 experienced cardiovascular events and 574 did not. The incidence of cardiovascular events in our sample population was 18%. As shown in Table 1, we found the following factors were highly associated with the odds of new-onset of CEs: advanced age in years, males, non-Hispanic African American, presence of comorbidities, and decreased saturation levels. Numerous laboratory values were significantly associated with the risk of CEs (Table 1).African Americans had greater odds of CEs in the presence of diabetes and cardiovascular comorbidities (p=0.008, p=0.014, respectively). However, multiple logistics analysis was used to examine the joint effect of the risk factors which suggested that lower serum albumin and neoplastic/immune compromised diseases count were highly associated with CEs for African American COVID-19 inpatients (p=0.001, p=0.044, respectively). SaO2/FiO2 ratio and cardiovascular comorbidities were significantly associated with CEs for white inpatients (p=<0.001, p=0.007, respectively).As shown in Figure 1, Kaplan-Meier survival analysis revealed inpatients with CEs had a much higher mortality rate than those without CEs (45.2% vs. 8.7%). Median survival for patients with CEs was 18 days as opposed to 100 days for those that did not experience CEs. African Americans with CEs experienced higher mortality than those without CEs (43.9% vs. 7.8%). White COVID-19 inpatients' mortality rates were 46.3% and 9.0% for those with and without CEs, respectively.Of the 126 COVID-19 inpatients who had a CE, 14.3% had cardiac arrhythmias and 8.7% had new onset of HF diagnoses, and 4.8% had acute myocardial infarctions.ConclusionMultiple risk factors for CEs and death were identified in this sample of hospitalized patients with COVID-19, and mortality was increased significantly in those inpatients who had CEs. HF, cardiac arrhythmia, and acute myocardial infarction were the most frequently cited CEs implicating the need for long-term follow-up.

Heartbeat: hospitalisation for COVID-19 is associated with an increased risk of subsequent adverse cardiovascular events

Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank

Cardiovascular outcomes for people hospitalised with COVID‐19 in Australia, and the effect of vaccination: an observational cohort study

The incidence of cardiovascular conditions in patients admitted to hospital with and without COVID-19 in the South-East of Scotland

Long-term cardiovascular outcomes of COVID-19

Long COVID and cardiovascular disease: a prospective cohort study

Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK Biobank

Risk of major adverse cardiovascular events after SARS-CoV-2 infection in British Columbia: a population-based study

Long-term effects of coronavirus disease 2019 on the cardiovascular system: the CV COVID-19 registry

Emergency Visits or Hospitalizations for Cardiovascular Diagnoses in the Post-Acute Phase of COVID-19

Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales

P014. Risk Factors for Cardiovascular Events In Hospitalized Patients with COVID-19

Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease

Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19

Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry)

Outcomes of Covid-19 among patients with ischemic heart disease: A propensity matched analysis

Adjudicated cardiovascular events in a cotemporary multicenter cohort of patients with COVID-19: findings from the CORONA-VTE Registry

Persistent increase of cardiovascular and cerebrovascular events in COVID-19 patients: a 3-year population-based analysis

Atrial fibrillation is a risk factor for major adverse cardiovascular events in COVID-19

Association of COVID-19 and influenza vaccinations and cardiovascular drugs with hospitalisation and mortality in COVID-19 and Long COVID: 2-year follow-up of 17 million individuals in England

Risk of Cardiovascular Events After COVID-19